Risk factors
Alkermes (ALKS) risk factors
Item 1A of every Alkermes plc 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors43 risks4 new3 dropped11 reworded
Integration risks and $1.525 billion debt from the Avadel acquisition dominate the updated risk factors.
Filed Feb 25, 2026 - FY2024 10-K risk factors42 risks
Alkermes relies heavily on commercial sales of proprietary neuroscience products like VIVITROL, ARISTADA, and LYBALVI. The company faces significant intellectual property, pricing, and manufacturing compliance risks.
Filed Feb 12, 2025